Key points are not available for this paper at this time.
Chronic stress is a significant risk factor that contributes to the progression of colorectal cancer (CRC) and has garnered considerable attention in recent research. It influences the distribution and function of immune cells within the intestinal mucosa through the "brain-gut" axis, altering cytokine and chemokine secretion and creating an immunosuppressive tumor microenvironment. The intestine, often called the "second brain," is particularly susceptible to the effects of chronic stress. Cytokines and chemokines in intestinal mucosal immunity（IMI） are closely linked to CRC cells' proliferation, metastasis, and drug resistance under chronic stress. Recently, antidepressants have emerged as potential therapeutic agents for CRC, possibly by modulating IMI to restore homeostasis and exert anti-tumor effects. This article reviews the role of chronic stress in promoting CRC progression via its impact on intestinal mucosal immunity, explores potential targets within the intestinal mucosa under chronic stress, and proposes new approaches for CRC treatment. ● Chronic stress affects cytokine and chemokine levels in the intestinal mucosa, which supports CRC cell growth and metastasis. ● Antidepressants may offer CRC treatment benefits by modulating chronic stress-induced immune changes in the intestinal mucosa. ● The review proposes targeting intestinal cytokine and chemokine under chronic stress as a potential approach for CRC therapy.
Yang et al. (Tue,) studied this question.